Spots Global Cancer Trial Database for Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Official Title: Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension: A Chinese Multicentre Retrospective Cohort Study
Study ID: NCT06245798
Conditions
Interventions
Study Description
Brief Summary: Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. HCC patients with CPSH are heterogeneous and treatment allocation remains controversial. The aim of this study was to compare the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in these populations.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tangdu hospital, Xian, Shaanxi, China
Xijing hospital, Xian, Shaanxi, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
